(Q37866341)

24 August 2017

1 reference

title

A review of tumour lysis syndrome with targeted therapies and the role of rasburicase (English)

1 reference

24 August 2017

P Bose

1

1 reference

24 August 2017

O Qubaiah

series ordinal

2

1 reference

24 August 2017

publication date

19 April 2011

1 reference

Journal of Clinical Pharmacy and Therapeutics

24 August 2017

published in

1 reference

24 August 2017

volume

36

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

299-326

1 reference

Tumor lysis syndrome: current perspective

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumour lysis syndrome in solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome in small cell carcinoma and other solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Managing tumor lysis syndrome in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumour lysis syndrome: new therapeutic strategies and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Prognostic significance of acute renal injury in acute tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rasburicase for the treatment and prevention of hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Optimizing management of tumor lysis syndrome in adults with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Renal tubular damage in rasburicase: risks of alkalinisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Spotlight on rasburicase in anticancer therapy-induced hyperuricemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rasburicase: a potent uricolytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Urate-oxidase in the prevention and treatment of metabolic complications in patients with B-cell lymphoma and leukemia, treated in the Société Française d'Oncologie Pédiatrique LMB89 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Clarifying the role of rasburicase in tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Advances in the management of malignancy-associated hyperuricaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Management of tumor lysis syndrome: need for evidence-based guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Is rasburicase needed for prevention of tumor lysis syndrome during treatment of less aggressive hematolymphoid malignancies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Consensus conference on the management of tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Catastrophic tumour lysis syndrome following single dose of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome during treatment with AMN107 (Nilotinib) in a patient with chronic myelogenous leukemia accelerated phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

21 January 2018

Sorafenib and sunitinib.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Cetuximab: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Recent advances of IMiDs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome in a multiple myeloma treated with thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Clinical development of novel proteasome inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Bortezomib-induced tumor lysis syndrome in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Bortezomib-associated tumor lysis syndrome in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Bortezomib Plus Thalidomide for Newly Diagnosed Multiple Myeloma in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Epigenetic modifiers: basic understanding and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Use of single-dose rasburicase in an obese female

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Treatment of impending tumor lysis with single-dose rasburicase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Tumor lysis syndrome associated with reduced immunosuppression in a lung transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Rasburicase and Tumor Lysis Syndrome: Lower Dosage, Consideration of Indications, and Hyperhydration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

Acute tumor lysis syndrome in large B-cell non-Hodgkin lymphoma induced by steroids and anti-CD 20

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2011.01260.X

10.1111/J.1365-2710.2011.01260.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference